Exhibit
10.90

# FIRST
AMENDMENT TO REGISTRATION RIGHTS AGREEMENT

This First
Amendment (this Amendment) to that certain Registration
Rights Agreement (the Agreement), dated December 13, 2005, by
and among Global Med Technologies, Inc., a Colorado corporation (the
Company) and each purchaser set forth on the signature pages
thereto and hereto (each, including its successors and assigns, a
Purchaser, collectively, the Purchasers
and together with the Company, the Parties and each a
Party) is made effective as of March 29, 2006.

# WITNESSTH:

WHEREAS,
the Parties desire to amend the Agreement as set forth herein.

NOW,
THEREFORE, in consideration of the mutual promises, conditions and covenants
contained herein and in the Agreement, and for other good and valuable
consideration, receipt of which is hereby acknowledged, the Parties hereto agree
as follows:

# AMENDMENT:

1.    
Amendment to Section 2. The Agreement is hereby amended by deleting Sections 2(a)
and (b) in their entirety and by inserting in lieu thereof the following:

| | (a)
On or prior to each Filing Date, the Company shall prepare and file with the
Commission a Shelf Registration Statement covering the resale of
130% of the Registrable Securities on such Filing Date for an offering to be
made on a continuous basis pursuant to Rule 415. The Registration Statement
shall be on Form S-3 (except if the Company is not then eligible to register for
resale the Registrable Securities on Form S-3, in which case such registration
shall be on another appropriate form in accordance herewith) and shall contain
(unless otherwise directed by the Holders) substantially the Plan of
Distribution attached hereto as Annex A. Subject to the terms
of this Agreement, the Company shall use its best efforts to cause a
Registration Statement to be declared effective under the Securities Act as
promptly as possible after the filing thereof, but in any event prior to the
applicable Effectiveness Date, and shall use its best efforts to keep such
Registration Statement continuously effective under the Securities Act until all
Registrable Securities covered by such Registration Statement have been sold or
may be sold without volume restrictions pursuant to Rule 144(k) as determined by
the counsel to the Company pursuant to a written opinion letter to such effect,
addressed and acceptable to the Companys transfer agent and the affected
Holders (the Effectiveness Period). The Company shall
telephonically request effectiveness of a Registration Statement as of 5:00 pm
Eastern Time on a Trading Day. The Company shall immediately notify the Holders
via facsimile of the effectiveness of a Registration Statement on the same
Trading Day that the Company telephonically confirms effectiveness with the
Commission, which shall be the date requested for effectiveness of a
Registration Statement. The Company shall, by 9:30 am Eastern Time on the
Trading Day after the Effective Date (as defined in the Purchase Agreement),
file a Form 424(b)(5) with the Commission. Failure to so notify the Holder
within 1 Trading Day of such notification shall be deemed an Event under Section
2(b). The Company and the Holders hereby acknowledge that the Company filed a
Registration Statement (Registration Number 333-131388) on Form SB-2 on January
30, 2006 with the Commission registering 24,529,793 shares of Common Stock
pursuant to this Agreement, which subsequently was declared effective by the
Commission on February 13, 2006. The Company and the Holders acknowledge and
agree that the above referenced registered shares is sufficient to comply with
the Companys initial Registration Statement filing requirements as set
forth herein.
| | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

| | (b)
If: (i) a Registration Statement is not filed on or prior to its Filing Date (if
the Company files a Registration Statement without affording the Holders the
opportunity to review and comment on the same as required by Section 3(a), the
Company shall not be deemed to have satisfied this clause (i)), or (ii) the
Company fails to file with the Commission a request for acceleration in
accordance with Rule 461 promulgated under the Securities Act, within five
Trading Days of the date that the Company is notified (orally or in writing,
whichever is earlier) by the Commission that a Registration Statement will not
be reviewed, or not subject to further review, or (iii) prior to its
Effectiveness Date, the Company fails to file a pre-effective amendment and
otherwise respond in writing to comments made by the Commission in respect of
such Registration Statement within 10 Trading Days after the receipt of comments
by or notice from the Commission that such amendment is required in order for a
Registration Statement to be declared effective, or (iv) a Registration
Statement filed or required to be filed hereunder is not declared effective by
the Commission by its Effectiveness Date, or (v) after the Effectiveness Date, a
Registration Statement ceases for any reason to remain continuously effective as
to all Registrable Securities for which it is required to be effective, or the
Holders are not permitted to utilize the Prospectus therein to resell such
Registrable Securities for 10 consecutive calendar days but no more than an
aggregate of 15 calendar days during any 12-month period (which need not be
consecutive Trading Days) (any such failure or breach being referred to as an
Event, and for purposes of clause (i) the date on which such
Event occurs, or for purposes of clause (ii) the date on which such five Trading
Day period is exceeded, or for purposes of clause (iii) the date which such 10
Trading Day period is exceeded, or for purposes of clause (iv) the Effective
Date has not occurred on or before the 155th day after the Closing
Date, or for purposes of clause (v) the date on which such 10 or 15 calendar day
period, as applicable, is exceeded being referred to as Event
Date), then in addition to any other rights the Holders may have
hereunder or under applicable law, on each such Event Date and on each monthly
anniversary of each such Event Date (if the applicable Event shall not have been
cured by such date) until the applicable Event is cured, the Company shall pay
to each Holder an amount in cash, as partial liquidated damages and not as a
penalty, equal to (A) in connection with Events described in clauses (i)-(iii)
and (v) 1% of the aggregate purchase price paid by such Holder pursuant to the
Purchase Agreement for any Registrable Securities then held by such Holder and
(B) in connection with the Event described in clause (iv) 4% of the aggregate
purchase price paid by such Holder pursuant to the Purchase Agreement for any
Registrable Securities then held by such Holder; provided, however, that
in no event shall such partial liquidated damages for any one or more Events
cumulatively exceed the sum of 24% of the aggregate purchase price paid by the
Holder for Registrable Securities. If the Company fails to pay any partial
liquidated damages pursuant to this Section in full within seven days after the
date payable, the Company will pay interest thereon at a rate of 18% per annum
(or such lesser maximum amount that is permitted to be paid by applicable law)
to the Holder, accruing daily from the date such partial liquidated damages are
due until such amounts, plus all such interest thereon, are paid in full. The
partial liquidated damages pursuant to the terms hereof shall apply on a daily
pro-rata basis for any portion of a month prior to the cure of an Event. In no
event will the liquidated damages and the interest thereon cumulatively exceed
24%.
| | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

3.   Full Force and Effect. Except as expressly amended herein, all other terms and
provisions of the Agreement shall remain in full force and effect and are hereby
ratified and confirmed in all respects.

4.   Counterparts. This Amendment may be executed in one or more counterparts, each of
which such counterparts shall be deemed an original and all of which together shall
constitute one and the same Amendment.

6.   Further Amendments. The Agreement shall further be amended wherever appropriate to
reflect the changes indicated above.

7.   Recital. The Recital hereto is hereby incorporated into this Amendment as if fully
stated herein.

# [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

---

IN
WITNESS WHEREOF, each Party has executed this First Amendment to the
Registration Rights Agreement as of the date first written above.

|GLOBAL MED TECHNOLOGIES, INC.   |  | Address for Notice:            | 
|------------------------------- |  | ------------------------------ | 
|By:  /s/ Michael I. Ruxin, M.D. |  | 12600 West Colfax, Suite C-420 | 
|Name:  Michael I. Ruxin, M.D.   |  | Lakewood, CO 80215             | 
|Title: Chairman and CEO         |  | Phone: (303) 238-2000          | 
|                                |  | Fax: (303) 238-3368            | 
|                                |  |                                | 

With a
copy to (which shall not constitute notice):

Name of
Purchaser: Magnetar Capital Master Fund, LLCSignature of Authorized Signatory of
Purchaser: /s/ Paul SmithName of Authorized Signatory: Paul SmithTitle of
Authorized Signatory: General CounselEmail Address of Purchaser: notices@magnetar.com

Name of
Purchaser: Crestview Capital Master Fund, LLCSignature of Authorized Signatory of
Purchaser: /s/ Robert HoytName of Authorized Signatory: Robert HoytTitle of
Authorized Signatory: Managing MemberEmail Address of Purchaser: bob@crestviewcap.com

Name of
Purchaser: Fusion Capital Fund II, LLCSignature of Authorized Signatory of Purchaser:
/s/ Joshua B. SchienfeldName of Authorized Signatory:  Joshua B. SchienfeldTitle of
Authorized Signatory: PresidentEmail Address of Purchaser: jschienfeld@fusioncapital.com

Name of
Purchaser: Enable Growth PartnersSignature of Authorized Signatory of Purchaser:
/s/ Mitch LevineName of Authorized Signatory: Mitch LevineTitle of Authorized
Signatory: Managing PartnerEmail Address of Purchaser: mlevine@enablecapital.com

Name of
Purchaser: Enable Opportunity PartnersSignature of Authorized Signatory of Purchaser:
/s/ Mitch LevineName of Authorized Signatory: Mitch LevineTitle of Authorized
Signatory: Managing PartnerEmail Address of Purchaser: mlevine@enablecapital.com

Name of
Purchaser: Shepherd Investments International, LTDSignature of Authorized Signatory
of Purchaser: Michael A. RothName of Authorized Signatory: Michael A. RothTitle
of Authorized Signatory: Managing Member of its Investment ManagerEmail Address of
Purchaser: bdavidson@sf-capital.com

---